Previous close | 86.72 |
Open | 87.04 |
Bid | 84.87 x 900 |
Ask | 84.89 x 800 |
Day's range | 84.74 - 87.08 |
52-week range | 60.57 - 96.12 |
Volume | |
Avg. volume | 3,381,252 |
Market cap | 51.119B |
Beta (5Y monthly) | 1.10 |
PE ratio (TTM) | 36.56 |
EPS (TTM) | N/A |
Earnings date | N/A |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | N/A |
NYON, Switzerland, May 08, 2024--Edwards Lifesciences today announced the European launch of the SAPIEN 3 Ultra RESILIA valve, the only transcatheter aortic heart valve to incorporate the company’s breakthrough RESILIA tissue technology, designed to extend the valve’s durability.*
IRVINE, Calif., April 25, 2024--Edwards Lifesciences (NYSE: EW) today reported financial results for the quarter ended March 31, 2024.
IRVINE, Calif., April 18, 2024--Edwards Lifesciences (NYSE: EW) plans to announce its operating results for the quarter ended March 31, 2024 after the market closes on Thursday, April 25, 2024, and will host a conference call at 5:00 p.m. ET that day to discuss those results.